Articles tagged "Drug interaction"

2019 American Transplant Congress
Clinical Utility of a Pharmacogenomic Testing Tool among Kidney Transplant Recipients
S. LeCorchick, L. Lindberg, W. Stapley, S. Anand, D. Morris, T. Srinivas
Kidney/Pancreas Transplant Program, Intermountain Medical Center, Murray, UT
*Purpose: Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is the cornerstone of clinical workflow in the transplant clinic. We report on the clinical implementation of,…
2019 American Transplant Congress
CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing
A. Zarrinpar¹, T. Kee², P. Wang³, J. Khong³, U. Kim¹, J. Chong², J. B. Jeong³, A. T. Truong², S. Tan², B. K. Betzler², W. Ng², C. Ho³, D. Ho²
¹Surgery, University of Florida, Gainesville, FL, ²National University of Singapore, Singapore, Singapore, ³UCLA, Los Angeles, CA
*Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…
2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
S. C. Jordan¹, K. Kucher², M. Bagger², H. Hockey³, K. Wagner⁴, N. Ammerman¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Biometrics Matters Ltd, Hamilton, New Zealand, ⁴Novartis Institutes for BioMedical Research, Cambridge, MA
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…
2019 American Transplant Congress
Two-Year, Single Center, Retrospective Review of Herbal Supplement Use in Living Kidney Donors
N. Persun¹, D. Johnson¹, A. Leonberg-Yoo², J. Bahrainwala², P. P. Reese², D. M. Collins³, M. Houston³, A. Naji⁴, J. Trofe-Clark¹
¹Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Renal Division, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Surgery, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA
*Purpose: Herbal supplement use in the evaluation phase of live kidney donors (LKD) poses challenges to providers. No formal management guidelines exist. Herbal supplements can…
2019 American Transplant Congress
A Novel Apparatus Mimicking Hypertensive Kidney With Primary Cultured Human Kidney Cells Using Rotational Force: Application To In Vitro Drug Screening In Kidney Transplant Recipients
Y. Kim¹, S. Lee², J. Moon¹, J. Kim¹, M. Yu³, C. Lee⁴, Y. Kim¹, S. Yang⁵, J. Jeong¹, J. Seon¹
¹Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ²Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, ³Internal Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of, ⁴Internal Medicine, Cheju Halla General Hospital, Cheju, Korea, Republic of, ⁵Kidney Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Cell culture is an essential part of the development for various medical technologies such as identifying the cause of the disease and developing new…
2019 American Transplant Congress
The Safety Of Adjuvant Chemotherapy In Kidney Transplant Patients With Urothelial Carcinoma
Z. Wang, J. Xiao, Y. Zhu, J. Lin, Y. Guo, Y. Tian
Capital Medical University，Beijing Friendship Hospital, Beijing, China
*Purpose: The purpose of the present study was to evaluate the safety of adjuvant chemotherapy with gemcitabine plus cisplatin in kidney transplant patients with urothelial…
2019 American Transplant Congress
A Retrospective Matched Case-Control Study of Medical and Psychiatric Outcomes in Kidney Transplant Recipients with Bipolar Disorder
A. GOSWAMI BANERJEE¹, S. Hamel², R. Weinrieb¹, S. Dave¹, V. Johnson³, D. Sawinski⁴, J. Trofe-Clark³
¹Psychiatry, Univ. of Pennsylvania, Philadelphia, PA, ²Vanderbilt Univ. Medical Center, Nashville, TN, ³Pharmacy, Hospital of the Univ. of Pennsylvania, Philadelphia, PA, ⁴Renal, Univ. of Pennsylvania, Philadelphia, PA
*Purpose: Management of kidney transplant recipients (KTRs) with bipolar disorder (BD) is complicated by risk factors for non-adherence, complex medication regimens and limited published guidance.…
2019 American Transplant Congress
Use of GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes
A. Kukla, J. Hill, M. Merzkani, A. Bentall, E. Lorenz, W. Park, P. Shah, N. Issa, M. Stegall
Mayo Clinic, Rochester, MN
*Purpose: GLP-1 receptor agonists have been shown to improve glucose control and diabetes-related comorbidities, including obesity, cardiovascular disease and chronic kidney disease, in non-transplant patients.…
2018 American Transplant Congress
Anti-IdeS Antibodies in IVIg and Its Effect on IdeS Activity
A. Runström,¹ S. Järnum,¹ S. Jordan,² L. Winstedt,¹ C. Kjellman.¹
¹Hansa Medical AB, Lund, Sweden; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles.
ObjectiveEvaluate how and why intravenous gamma globulin (IVIg) affects IdeS-cleavage of IgG.IntroductionIgG degrading enzyme of Streptococcus pyogenes (IdeS) cleaves human IgG in two steps, first…